Hyderabad: Aurobindo Pharma has announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company, has mutually agreed to terminate its agreement with BioFactura Inc, USA relating to BFI-751, the proposed ustekinumab biosimilar product.
The company said the decision follows CuraTeQ’s strategic portfolio prioritisation and will not have any material impact on Aurobindo’s overall biosimilars strategy.
The agreement was executed on July 7, 2023, for commercialising BFI-751.
As per the license agreement, BioFactura would receive license fees spread across different milestones leading to commercialization in regulated markets and CuraTeQ to have global manufacturing rights.
Read also: Aurobindo Pharma arm to acquire 20% additional ownership in Luoxin Aurovitas for Rs 45 crore
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a R&D set-up.